Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome
Authors:
- 16 December 2008
- journal article
- research article
- Published by Wiley in Neurourology and Urodynamics
- Vol. 28 (1) , 47-51
Abstract
Aims: To investigate whether vaginal estrogen cream combined with tolterodine is more effective than tolterodine alone in the treatment of postmenopausal women with overactive bladder (OAB).Materials and Methods: This is an unblinded study without placebo. A preliminary study consisted of tolterodine 2 mg twice per day for 3 months had been conducted for 25 postmenopausal women with OAB. Over a period of 11 months, 80 postmenopausal women with OAB underwent a prospective randomized trial. These patients were equally randomized into two groups. The interventions for the 12‐week treatment period included 2 mg tolterodine twice per day for the group A and 2 mg tolterodine twice per day/vaginal conjugated equine estrogen 0.625 mg twice a week for the group B. Identical pre‐ and post‐treatment assessments included bladder diary, Urogenital Distress Inventory‐6 (UDI‐6), and Incontinence Impact Questionnaire‐7 (IIQ‐7).Results: All 80 women (65.2 years, range 58–73) completed this study. The between groups comparison showed that the group B had significant improvements in mean daytime frequency and voided volume after treatment (14.8–5.8 vs. 14.1–6.4, P = 0.001 and 115.8–141.9 vs. 108.5–134.5, P = 0.007, respectively). Additionally, a comparison of the final total scores of UDI‐6 and IIQ‐7 between the two groups revealed that the group B had a statistically significant improvement in quality of life than that in the group A (8.6–6.9 vs. 9.5–7.2, P < 0.001 and 9.4–6.1 vs. 10.2–6.5, P < 0.001, respectively). Changes in the other symptoms, including nocturia, urgency and urge incontinence, were not statistically significant but actually achieved improved in both groups.Conclusions: A combination of vaginal estrogen cream and tolterodine is a potential therapy for postmenopausal women with OAB. Neurourol. Urodynam. 28:47–51, 2009.Keywords
This publication has 26 references indexed in Scilit:
- A randomized comparative study of the effects of oral and topical estrogen therapy on the lower urinary tract of hysterectomized postmenopausal womenFertility and Sterility, 2006
- Vaginal estrogen therapy and overactive bladder symptoms in postmenopausal patients after a tension-free vaginal tape procedure: a randomized clinical trialMenopause, 2005
- Antimuscarinic agents: Implications and concerns in themanagement of overactive bladder in the elderlyClinical Therapeutics, 2005
- Clinical efficacy of tolterodine with or without a simplified pelvic floor exercise regimenNeurourology and Urodynamics, 2003
- Prevalence and correlation of urinary incontinence and overactive bladder in Taiwanese womenNeurourology and Urodynamics, 2003
- The effect of oestradiol on vaginal collagen metabolism in postmenopausal women with genuine stress incontinenceBJOG: An International Journal of Obstetrics & Gynaecology, 2002
- The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence SocietyNeurourology and Urodynamics, 2002
- Risk Factors for Urinary Incontinence in Both SexesEuropean Urology, 2001
- Vaginal oestradiol for the treatment of lower urinary tract symptoms in postmenopausal womena double-blind placebo-controlled studyJournal of Obstetrics and Gynaecology, 2001
- Zur Wirksamkeit einer intravaginalen Östrioltablettenapplikation bei Frauen mit Urge-InkontinenzGeburtshilfe und Frauenheilkunde, 1991